Novo Nordisk upgraded to Market Perform at Bernstein on valuation
As previously reported, Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform with a price target of DKK 600, up from DKK ...
Novo Nordisk price target lowered to DKK 725 from DKK 975 at Berenberg
Berenberg lowered the firm’s price target on Novo Nordisk (NVO) to DKK 725 from DKK 975 and keeps a Hold rating on the shares.Don't Miss Our ...
pharmaphorum4d
Novo Nordisk sheds billions in value on obesity data
Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.